AJMC
Issue:
November 2012
Volume:
18
Number:
11
CLINICAL
David H. Smith, RPh, PhD; Adrianne C. Feldstein, MD, MS; Nancy Perrin, PhD; A. Gabriela Rosales, MS; David M. Mosen, PhD, MPH; Elizabeth G. Liles, MD; Jennifer L. Schneider, MPH; Jennifer E. Lafata, PhD; Ronald E. Myers, PhD; and Russell E. Glasgow, PhD
Automated telephone calls can increase colorectal cancer screening rates at a cost of about $40 per additional screen.
Katrina A. B. Goddard, PhD; Erin J. Aiello Bowles, MPH; Heather Spencer Feigelson, PhD, MPH; Laurel A. Habel, PhD; Sharon Hensley Alford, PhD; Catherine A. McCarty, PhD, MPH; Larissa Nekhlyudov, MD, MPH; Adedayo A. Onitilo, MD, MSCR, FACP; Alanna K. Rahm, PhD, MS; and Jennifer A. Webster, MS
Evaluation of real-world implementation of HER2 testing showed that uptake was high (>90%) and trastuzumab treatment was targeted to patients with positive HER2 status.
COMMENTARY
Sarah Thomas, MS; and Margaret O’Kane, MHS
Purchasers-employers and government programs-are primary actors for pushing for payment, benefit design, and transparency initiatives to get better value; health plans can partner.
MANAGERIAL
Charity Evans, PhD; Elaine Kingwell, PhD; Feng Zhu, MSc; Joel Oger, MD, FRCPC, FAAN; Yinshan Zhao, PhD; and Helen Tremlett, PhD
An examination of hospitalization patterns in patients with multiple sclerosis with a focus on the association with time and patient characteristics.
METHODS
Hsien-Yen Chang, PhD; Jonathan P. Weiner, DrPH; Thomas M. Richards, MSEE; Sara N. Bleich, PhD; and Jodi B. Segal, MD, MPH
The aDCSI without the inclusion of laboratory data performs similarly to the DCSI with laboratory results, and is a good measure of diabetes severity.
POLICY
Thomas J. Flottemesch, PhD; Louise H. Anderson, PhD; Leif I. Solberg, MD; Patricia Fontaine, MD, MS; and Stephen E. Asche, MA
From 2005 to 2009, improved clinical practice systems were associated with cost reductions only for medically complex patients.